Skip to main content

Table 1 Characteristics of patients with candidaemia and univariate analysis for all cause 30-day mortality

From: Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study

  No. patients (total = 133) 30-day mortality Odds ratio, 95% confidence interval P value
Age > 65 years 57 (43) 24 (42) 2.7 (1.3–5.8) 0.01
Male gender 76 (57) 24 (32) 1.1 (0.5–2.3) 0.8
Female gender 57 (43) 17 (30) 0.9 (0.4–1.9) 0.8
Setting of candidaemia
 IHCA 113 (85) 35 (31) 1 .0 (0.4–3.0) 0.9
 OHCA 13 (10) 3 (23) 0.6 (0.2–2.5) 0.6
 CA 7 (5) 3 (43) 0.6 (0.2–2.5) 0.5
Admitting service
 Medical 77 (58) 30 (39) 2.6 (1.2–5.8) 0.02
 Surgical 56 (42) 11 (20) 0.4 (0.2–0.8) 0.02
 ICU admission 55 (41) 22 (40) 2.1 (1.0–4.4) 0.06
Co-morbidities
 Haematologic malignancy 20 (15) 10 (50) 2.6 (1.0–7.0) 0.06
 Allogeneic stem cell transplantation 2 (1) 1 (50) 2.3 (0.1–37.3) 0.6
 Solid organ malignancy 25 (19) 7 (28) 0.8 (0.3–2.2) 0.7
 Solid organ transplantation 5 (4) 1 (20) 0.5 (0.1–5.0) 0.6
 Diabetes mellitus 33 (25) 10 (30) 1.0 (0.4–2.3) 0.9
 Chronic organ dysfunction 50 (38) 29 (58) 0.4(0.2–0.9) 0.03
 Renal disease 18 (14) 8 (44) 2.0 (0.7–5.5) 0.2
 Liver disease 15 (11) 5 (33) 1.1 (0.4–3.6) 0.8
 Cardiovascular disease 26 (20) 11 (42) 1.8 (0.8–4.6) 0.2
 Respiratory disease 11 (8) 5 (45) 2.0 (0.6–6.9) 0.3
Predisposing factors
 Surgery 69 (52) 16 (23) 0.5 (0.2–1.0) 0.05
 Gastrointestinal surgery 35 (26) 11 (31) 1.0 (0.4–2.4) 0.9
 Urinary catheter 80 (60) 15 (19) 1.6 (0.7–3.6) 0.2
 CVAD 98 (74) 30 (31) 1.0 (0.4–2.2) 0.9
 Hyperalimentation 27 (20) 5 (19) 0.4 (0.2–1.3) 0.1
 Corticosteroids or other immunosuppressant 36 (27) 13 (36) 1.4 (0.6–3.1) 0.4
 Intravenous drug use 13 (10) 1 (8) 0.2 (0.02–1.3) 0.1
 Use of antibiotic agents ≥10 days 39 (29) 16 (41) 1.9 (0.9–4.2) 0.1
 Prior antifungal usea 19 (14) 7 (37) 1.4 (0.5–3.8) 0.5
 Sepsis syndrome 97 (73) 29 (30) 0.9 (0.4–1.9) 0.5
Source of candidaemia
 Intravascular 42 (32) 9 (21) 0.5 (0.2–1.2) 0.1
 Gastrointestinal 46 (35) 19 (41) 2.1 (1.0–4.4) 0.06
 Urologic 27 (20) 2 (7) 0.1 (0.03–0.6) 0.009
 Unknown 18 (14) 11 (61) 4.4 (1.6–12.5) 0.005
Candida species
Candida albicans 52 (39) 17 (33) 1.2 (0.5–2.4) 0.7
Candida glabrata complex 43 (32) 15 (35) 1.4 (0.5–3.8 0.5
Candida parapsilosis complex 13 (10) 1 (8) 0.2 (0.02–1.3) 0.09
 Other Candida species b 25 (19) 8 (32) 1.1 (0.4–2.7) 0.9
  1. Counts are shown as n (%) unless otherwise stated
  2. CA community acquired, CVAD Central venous access device, IHCA inpatient healthcare associated, ICU intensive care unit, OHCA outpatient healthcare associated
  3. a Antifungals used prior to diagnosis of candidaemia included fluconazole in 15 patients, voriconazole in 1, anidulafungin in 1, caspofungin as prophylaxis in 2 and voriconazole for treatment of possible pulmonary aspergillosis in 1
  4. b C. tropicalis (n = 10), C, krusei (n = 5), C. robusta (n = 1), C. dubliniensis (n = 1), C. lipolytica (n = 1), C. lusitaniae (n = 1), more than 1 Candida spp. (n = 6); these were C. albicans and C. glabrata sensu stricto (n = 2), C. albicans and C. bracariensis (n = 1), C. albicans and C. nivariensis (n = 1), C. albicans and C. parapsilosis sensu stricto (n-1), and C. albicans,C. parapsilosis sensu stricto and C. tropicalis (n = 1)
\